Want to see FR:AELIS full AI Analyst Report?
Top Page
Aelis Farma SA
(AELIS)
Select Model
Select Model
Rating:42Neutral
Price Target:
€0.71
▼(-29.70% Downside)
Action:Upgraded
Date:10/30/26
The score is held down primarily by weak financial performance (multi-year losses, deteriorated profitability, and ongoing cash burn with equity erosion), reinforced by a clearly negative technical trend. Valuation contributes only modestly because a negative P/E and missing dividend data provide limited positive support.
Positive Factors
Focused therapeutic platform
A focused platform around endocannabinoid-system modulation gives Aelis a clearly defined scientific direction and potential to build expertise across related neurological and peripheral indications. Its lead program targets cannabis use disorder through a differentiated mechanism intended to reduce THC effects while preserving normal signaling.
Negative Factors
Declining and volatile revenue
Falling and volatile revenue indicates that the current business base is not yet providing a dependable platform for funding operations. Revenue well below 2023 levels makes recovery dependent on future commercialization or development progress, increasing uncertainty around the path to sustainable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused therapeutic platform
A focused platform around endocannabinoid-system modulation gives Aelis a clearly defined scientific direction and potential to build expertise across related neurological and peripheral indications. Its lead program targets cannabis use disorder through a differentiated mechanism intended to reduce THC effects while preserving normal signaling.
Read all positive factors
Aelis Farma SA (AELIS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€9.91M
Dividend YieldN/A
Average Volume (3M)14.01K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth-97.09%
EPS Growth45.00%
CountryFR
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.33
Shares Outstanding13,706,586
10 Day Avg. Volume15,814
30 Day Avg. Volume14,013
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)3.49
Price to Sales (P/S)7.43
P/FCF Ratio-2.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)€12.40M
Aelis Farma SA Business Overview & Revenue Model
Company Description
Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-sp...
Aelis Farma SA Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
41
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.64M | 2.08M | 2.68M | 9.05M | 3.81M | 9.07M |
| Gross Profit | -3.10M | -279.00K | 2.68M | 9.05M | 3.81M | 9.07M |
| EBITDA | -7.08M | -8.00M | -7.18M | -6.35M | -16.23M | 844.00K |
| Net Income | -4.52M | -6.43M | -7.46M | -5.08M | -14.29M | 574.00K |
Balance Sheet | ||||||
| Total Assets | 8.44M | 12.05M | 19.71M | 26.28M | 39.22M | 28.31M |
| Cash, Cash Equivalents and Short-Term Investments | 6.62M | 8.21M | 14.05M | 20.23M | 34.40M | 24.71M |
| Total Debt | 4.38M | 6.60M | 6.25M | 4.04M | 3.82M | 6.41M |
| Total Liabilities | 6.12M | 7.61M | 9.59M | 13.08M | 19.43M | 27.41M |
| Stockholders Equity | 2.31M | 4.44M | 10.12M | 13.20M | 19.79M | 899.00K |
Cash Flow | ||||||
| Free Cash Flow | -3.48M | -5.39M | -11.72M | -12.67M | -13.19M | 18.76M |
| Operating Cash Flow | -3.48M | -5.38M | -11.53M | -12.59M | -13.05M | 18.97M |
| Investing Cash Flow | -837.00K | -841.00K | -190.00K | -88.00K | -86.00K | -212.00K |
| Financing Cash Flow | -703.00K | 538.00K | 5.81M | -1.34M | 22.10M | 180.00K |
Aelis Farma SA Technical Analysis
Negative
1.01
Price Trends
0.87
Negative
0.96
Negative
1.13
Negative
Market Momentum
-0.05
Negative
38.98
Neutral
65.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AELIS, the sentiment is Negative. The current price of 1.01 is above the 20-day moving average (MA) of 0.74, above the 50-day MA of 0.87, and below the 200-day MA of 1.13, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 38.98 is Neutral, neither overbought nor oversold. The STOCH value of 65.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:AELIS.
Aelis Farma SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | €8.87M | -0.43 | 33.88% | ― | ― | ― | |
46 Neutral | €18.98M | -1.06 | 52.39% | ― | -610.31% | 43.88% | |
42 Neutral | €9.91M | -2.19 | ― | ― | -97.09% | 45.00% | |
42 Neutral | €11.52M | -0.02 | 153.48% | ― | ― | 90.97% | |
37 Underperform | €9.42M | 217.14 | -0.18% | ― | 0.10% | 99.69% |
* Healthcare Sector Average
FR:AELIS
Aelis Farma SA
0.72
-0.41
-36.02%
FR:POXEL
Poxel SA
0.17
-0.17
-50.30%
FR:SIGHT
GenSight Biologics SA
0.08
-0.05
-38.89%
FR:ALDVI
Advicenne SA
0.65
-1.06
-61.99%
FR:ALBPS
Biophytis SA
0.03
-0.08
-71.70%
FR:ALNFL
NFL Biosciences SA
0.45
-0.70
-60.73%
Aelis Farma SA Corporate Events
Aelis Farma Publishes 2026 Half-Year Financial Report
Sep 24, 2026
Aelis Farma announced that its 2026 half-year financial report has been filed with the French Financial Markets Authority and is now available to the public on the company’s website. The publication offers investors and stakeholders updated ...
Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances
Sep 15, 2026
In the first half of 2026, Aelis Farma advanced its clinical priorities, most notably the international Phase 2b trial of AEF0217 in people with Down syndrome, with recruitment on track and a positive safety committee recommendation. A key regulat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.